scispace - formally typeset
Search or ask a question
Author

Alaide Jiménez Serna

Bio: Alaide Jiménez Serna is an academic researcher. The author has contributed to research in topics: Microbiome. The author has co-authored 1 publications.
Topics: Microbiome

Papers
More filters
Journal ArticleDOI
TL;DR: A review of the developments in the area of cancer prevention and treatment, intimately related to advances in the knowledge of the microbiome role in its genesis and therapy is presented in this paper.
Abstract: Probiotics were defined as microbial strains that confer health benefits to their consumers. The concept has evolved during the last twenty years, and today metabolites produced by the strains, known as postbiotics, and even dead cells, known as paraprobiotics are closely associated to them. The isolation of commensal strains from human microbiome has led to the development of next generation probiotics. This review aims to present an overview of the developments in the area of cancer prevention and treatment, intimately related to advances in the knowledge of the microbiome role in its genesis and therapy. Strain identification and characterization, production processes, delivery strategies and clinical evaluation are crucial to translate results into the market with solid scientific support. Examples of recent tools in isolation, strain typification, quality control and development of new probiotic strains are described. Probiotics market and regulation were originally developed in the food sector, but these new strategies will impact the pharmaceutical and health sectors, requiring new considerations in regulatory frameworks.

5 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The overall data suggest the bio-therapeutic potential of the identified vaginal probiotics against cervical cancer-associated pathogens is higher than previously suggested.

1 citations

Journal ArticleDOI
TL;DR: The review increases the understanding of the health improvements of mineral-enriched postbiotics, including antioxidant functions, highlighting their perspective on microbial therapy to prevent and threaten gut-related diseases.
Abstract: Postbiotics are non-viable probiotic preparations that confer a health benefit on the host. In the last years, scientific literature has proved that postbiotics have health-promoting features and technological advantages compared to probiotics, augmenting their full potential application in the food and pharmaceutical industries. The current work comprehensively summarizes the benefits and potential applications of postbiotics and essential mineral-enriched biomass and proposes a new strategy for microbial therapy—mineral-enriched postbiotics. We hypothesize and critically review the relationship between micronutrients (calcium, magnesium, iron, zinc, selenium) and postbiotics with gut microbiota, which has been barely explored yet, and how the new approach could be involved in the gut microbiome modulation to prevent and treat gut dysbiosis. Additionally, the bioactive molecules and minerals from postbiotics could influence the host mineral status, directly or through gut microbiota, which increases the mineral bioavailability. The review increases our understanding of the health improvements of mineral-enriched postbiotics, including antioxidant functions, highlighting their perspective on microbial therapy to prevent and threaten gut-related diseases.

1 citations

Journal ArticleDOI
TL;DR: In this article , a cell proliferation assay and scanning electron microscopy were used to detect changes in the viability of SW480, Caco-2, and HCT-116 colorectal cancer cells treated with plantaricin BM-1.
Abstract: Plantaricin BM-1 is a class IIa bacteriocin produced by Lactobacillus plantarum BM-1 that has significant antimicrobial activity against food-borne bacteria. In this study, a cell proliferation assay and scanning electron microscopy were used to detect changes in the viability of SW480, Caco-2, and HCT-116 colorectal cancer cells treated with plantaricin BM-1. We found that plantaricin BM-1 significantly reduced the viability of all colorectal cancer cell lines tested, especially that of the SW480 cells. Scanning electron microscopy showed that plantaricin BM-1 treatment reduced the number of microvilli and slightly collapsed the morphology of SW480 cells. Fluorescence microscopy and flow cytometry demonstrated that plantaricin BM-1 induced apoptosis of SW480 cells in a concentration-dependent manner. Western blotting further showed that plantaricin BM-1-induced apoptosis of SW480 cells was mediated by the caspase pathway. Finally, transcriptomic analysis showed that 69 genes were differentially expressed after plantaricin BM-1 treatment (p < 0.05), of which 65 were downregulated and four were upregulated. The Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that expression levels of genes involved in the TNF, NF-κB, and MAPK signaling pathways, as well as functional categories such as microRNAs in cancer and transcriptional misregulation in cancer, were affected in SW480 cells following the treatment with plantaricin BM-1. In conclusion, plantaricin BM-1 induced death in SW480 cells via the caspase-dependent apoptosis pathway. Our study provides important information for further development of plantaricin BM-1 for potential applications in anti-colorectal cancer.
Book ChapterDOI
01 Jan 2023
TL;DR: In this paper , the authors summarize the involvement of intestinal microbiota in GI cancer development, the potential mechanism of actions of probiotics/prebiotics, and related preclinical and clinical studies in the prevention and treatment of GI cancers to highlight their potential therapeutic values.
Abstract: Gastrointestinal (GI) cancers are major public health problems as they are one of the most common types of cancer worldwide. Despite recent treatment advancements due to a better understanding of the molecular mechanisms of GI cancer tumorigenesis, a high mortality rate still occurs, especially in the metastatic stage of GI cancers. Modulating intestinal microbiota with probiotics and prebiotics becomes a novel strategy for the prevention and treatment of GI cancers as intestinal microbiota has been shown to play a key role in GI cancer development. The literature has provided ample evidence that probiotics could help to prevent or treat GI cancers by slowing down the progression or acting as adjunctive therapy to cancer treatment. In this chapter, we summarize the involvement of intestinal microbiota in GI cancer development, the potential mechanism of actions of probiotics/prebiotics, and related preclinical and clinical studies in the prevention and treatment of GI cancers to highlight their potential therapeutic values.